Success Stories: Thanks to Our Experts, an Associate Professor from Taiwan Working in Pathology with Over 2,900 Citations for his Publications Obtains NIW Confirmation without RFE

 

Client’s Testimonial:

“Thank you very much, and it was my pleasure to work with such a great team.”

---

On April 4^th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for an Associate Professor in the Field of Pathology (Approval Notice).

---

General Field: Pathology

Position at the Time of Case Filing: Associate Professor

Country of Origin: Taiwan

Country of Residence at the Time of Filing: Taiwan

Approval Notice Date: April 4^th, 2022

Processing Time: 3 months, 13 days

---

Case Summary:

As an expert in the field of pathology, our NIW (National Interest Waiver) client from Taiwan’s proposed endeavor was to continue to develop comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for precision in the treatment of cancer. So, it was apparent that his proposed endeavor is of great importance because it contributes to the effective treatment of gynecological cancers such as ovarian cancer. Gynecological cancers account for nearly one-fifth of all new cancer cases worldwide and cause just under 3 million deaths annually.

Our team had the task to ensure the success of his case and we did so by making a list of his achievements. This list contained the following data which helped in the quick adjudication of his case:

• His proposed research of developing comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for the precision treatment of cancer, therefore, has substantial merit.
• His proposed endeavor also has broad implications for the United States. His research on cancer treatments, generally, disproportionately benefits the United States, which has a high age-adjusted cancer rate compared to most other countries.
• Due to its clear national importance, his research has in fact been supported with funding from the United States Department of Defense, the National Institutes of Health, the American Cancer Society, the Honorable Tina Brozman Foundation, the Ovarian Cancer Research Alliance, the Gray Foundation, and the John Templeton Foundation.
• He has completed at least 13 reviews to date for well-known journals in his area of study.
• His research has resulted in 116 peer-reviewed journal articles (14 of them first-authored and 3 corresponding-authored).
• His publications have been cited a massive total of 2,919 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pathology.
• He has pursued research directly related to his proposed endeavor of developing comprehensive molecular profiling approaches to discovering diagnostic biomarkers and therapeutic targets for the precision treatment of cancer for 11 years.

While these specific research contributions represent only a subset of his most successful endeavors, these projects are indicative of the overall quality of his research and illustrate his particular expertise and ability to continue contributing significantly to his field and to advancing the proposed endeavor. The evidence thus shows that his research holds significant value for the treatment of cancers and for the U.S. pharmaceutical industry. This argument helped our case and won him the NIW approval only 3 months and 13 days later.

---